A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke - CERE-LYSE-1

• Conditions: Clinical diagnosis of ischemic stroke causing a measurable neurological deficitdefined as impairment of language, motor function, cognition and/or gaze,vision or neglect. Ischemic stroke is defined as an event characterised by thesudden onset of an acute focal neurologic deficit presumed to be due tocerebral ischemia after CT scan excludes haemorrhage. Onset of symptoms within 3 hours prior to initiation of rt-PA administration; MedDRA version: 6.0Level: LLTClassification code 10055221

• Registration Number: EUCTR2004-001729-11-AT
• Lead Sponsor: EBEWE Pharma Ges.m.b.H Nfg.KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01-14
• Last Update Posted: 22 April 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

•Female or male inpatients.
•Age: 18-80 years.
•If female, patient must not be pregnant
•Clinical diagnosis of ischemic stroke causing a measurable neurological deficit
defined as impairment of language, motor function, cognition and/or gaze,
vision or neglect. Ischemic stroke is defined as an event characterised by the
sudden onset of an acute focal neurologic deficit presumed to be due to
cerebral ischemia after CT scan excludes haemorrhage.
•Onset of symptoms within 3 hours prior to initiation of rt-PA administration.
•Stroke symptoms are to be present for at least 30 minutes and have not
significantly improved before treatment. Symptoms must be distinguishable from an episode of generalised ischemia (i.e. syncope), seizure or migraine disorder.
•Patient is willing to participate voluntarily and to sign a written patient
informed consent. Informed consent will be obtained from each patient or the
subject's legally authorised representative or relatives, or deferred where
applicable, according to the regulatory and legal requirements of the
participating country.
•Patients who are unable to sign but who are able to understand the meaning of
participation in the study may give an oral witnessed informed consent. These
patients have to make clear undoubtfully that they are willing to participate
voluntarily and must be able to understand an explanation of the contents of the
information sheet. A written consent has to be obtained as soon as possible.
•Willingness and ability to comply with the protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Evidence of intracranial haemorrhage (ICH) on the CT-scan
•Violation of inclusion criteria not approved by clinical study director or study safety officer
•Failure to perform or to evaluate screening or baseline examinations
•Hospitalisation (except for study purposes) or change of concomitant medication 4 weeks prior to screening or during screening period
•Participation in another therapeutic clinical trial 3 months before baseline
•Patients with any history of prior stroke and concomitant diabetes
•Prior stroke within the last 3 months
•Platelet count of below 100x103/mm3
•Blood glucose <50 or >400 mg/dl (<2.77 or >22.15 mmol/L)
•Known haemorrhagic diathesis
•Manifest or recent severe or dangerous bleeding
•Known bacterial endocarditis, pericarditis
•Acute pancreatitis
•Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial-aneurysm, arterial/venous malformation
•Neoplasm with increased bleeding risk
•Severe liver disease, including hepatic failure, cirrhosis, portal hypertension, oesaphageal varices) and active hepatitis
•Major surgery or significant trauma in past 3 months
•Lab values seriously abnormal, and/or more than 2 lab values abnormal not approved by clinical study director or study safety officer
•Serious drug allergies
•Hypersensitivity to one of the components of the drug
•Severe renal impairment
•Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, or aggressive management (IV medication) necessary to reduce BP to these limits
•Recent (less than 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture)
•Chronic intoxication or chronic substance use disorder with pharmaceuticals, drugs, alcohol or industrial poisons
•Symptoms of ischemic attack began more than 3 hours prior to start of thrombolytic therapy or if time of symptom onset is unknown
•Minor neurological deficit or symptoms rapidly improving before start of infusion
•Severe stroke as assessed clinically (e.g. NIHSS >25) and/or by appropriate
imaging techniques
•Epilepsy or epileptic seizure at onset of stroke
•Symptoms suggestive of subarachnoid haemorrhage, even if the CT-scan is normal
•Known history of or suspected intracranial haemorrhage
•Suspected subarachnoid haemorrhage or condition after subarachnoid hemorrhage from aneurysm
•Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
•Haemorrhagic retinopathy, e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy)
•Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory
•Patients receiving oral anticoagulants, e.g. warfarin sodium
•Special attention should be given to possible additive effects when used in conjunction with anti-depressants or MAO-inhibitors
•Cerebrolysin should not be mixed with balanced amino acid solutions in an infusion

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified